Trade Summary

3 days ago, BENTSUR RON, serving as Chairman & CEO at Nuvectis Pharma, Inc. (NVCT), purchased 12,500 shares at $20.00 per share, for a total transaction value of $250,000.00. Following this transaction, BENTSUR RON now holds 3,688,424 shares of NVCT.

This purchase represents a 0.34% increase in BENTSUR RON's stake in the company.

The trade was executed on Tuesday, June 30, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, July 1, 2026 at 1:39 PM ET, 1 day after the trade was made.

Nuvectis Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.